April 12, 2024
Via: Biopharma DiveInitial public offerings by biotechnology companies reached pre-pandemic levels during the first quarter, with nine drugmakers collectively raising more than $1.3 billion, according to BioPharma Dive data. The sum is more than three times the $375 million in total proceeds […]
Biotech, Cell and Gene Therapy, Industry
April 11, 2024
Via: Biopharma DiveDrugmakers are moving quickly to study whether cell therapy, already a proven treatment for certain blood cancers, can tamp down autoimmune conditions, too. Lupus, a chronic disease that can cause inflammation and pain across the body, is one of the […]
February 14, 2024
Via: Biopharma DiveA little over four years ago, biotechnology giant Amgen retreated from neuroscience research, halting much of its work developing treatments for diseases of the brain and trimming associated staff. Amgen’s pivot proved a boon for a small startup that was […]
February 12, 2024
Via: Biopharma DiveSix biotechnology startups are merging into a new skin drug developer called Alys Pharmaceuticals, which launched on Monday with $100 million from European life sciences investment firm Medicxi. Alys was formed out of the merger of a group of biotechs […]
February 2, 2024
Via: Biopharma DiveArch Venture Partners, one of the biotechnology sector’s most prolific company creators, is raising a new $3 billion fund, according to a regulatory filing. The fund, which would be Arch’s 13th, is being put together less than two years after […]
January 26, 2024
Via: PharmaphorumWilmington, Delaware-based Synnovation, a specialist in small-molecule therapeutics for cancer, has emerged from the shadows with a $102 million first-round financing led by Third Rock Ventures with participation from Nextech, Lilly Asia Ventures, Sirona Capital and Cormorant Asset Management. The […]
January 24, 2024
Via: Biopharma DiveCancer drug developer CG Oncology has raised $380 million in an initial public offering than was larger than it expected, a positive sign for a sector that’s struggled to generate demand from Wall Street investors recently. The company on Wednesday […]
January 19, 2024
Via: PharmaphorumBlue Owl Capital and Canada Pension Plan Investment Board have stepped in to bulk up cash reserves at BridgeBio as it prepares for the launch of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) and a market showdown with much larger rival […]
January 18, 2024
Via: Biopharma DiveMirae Asset Capital Life Science, a new venture capital fund, launched on Thursday, joining several other new firms that have recently emerged with plans to invest in drug startups. The fund is a spinout of Mirae Asset Financial Group, a […]
January 17, 2024
Via: Biopharma DiveMore than two years after the bottom fell out for biotech stocks, the market for IPOs is showing early signs of life, though investors are generally looking for more well-established companies than in the past. Four of the five companies […]
January 16, 2024
Via: Biopharm InternationalCellVoyant—an artificial intelligence (AI) first biotechnology company spun out of the University of Bristol—has raised £7.6 million in seed funding to speed up the development of novel cell therapies. According to a Jan. 16, 2024 press release, the funding was […]
January 11, 2024
Via: Biopharma DiveThe J.P. Morgan Healthcare Conference, a yearly temperature taker for the biotechnology industry, had a different feel in 2024. For the first time in awhile, young drugmakers and their backers were optimistic the sector’s downturn might finally be over. An […]
January 9, 2024
Via: PharmaphorumThe deal – announced at the JP Morgan Healthcare conference this week – includes a sizeable $1 billion upfront payment, with up to $400 million more on the table if Aiolos’ pipeline delivers the results GSK is hoping for. AIO-001 […]
November 30, 2023
Via: Biopharma DiveFlagship Pioneering is looking to raise $3 billion for its eighth venture fund, a sign the high-profile company creator continues to see investor interest in the biotechnology sector despite a turbulent market. The plans were outlined in a securities document […]
October 30, 2023
Via: Biopharma DiveFor years, many of the world’s largest, most deep-pocketed pharmaceutical firms had cast brain drugs aside, opting instead to devote resources to less risky, often more lucrative areas of research like oncology and immunology. But recent scientific and technological breakthroughs, […]
October 26, 2023
Via: Biopharma DiveDespite optimism for a stronger investment climate this year, many of the hurdles that faced young biotechnology companies in late 2022 have endured through 2023. Initial public offerings for drugmakers have remained slow, with only 18 biotechs making their public […]
October 24, 2023
Via: Biopharma DiveWhen developing new medicines, drugmakers typically try to make treatments that are more effective, durable or safer than what’s already available. If they’re lucky, they can hit on something that meets at least one of those goals. Rampart Bioscience, a […]
October 3, 2023
Via: Biopharma DiveInitial public offerings may slowly be coming back to the biotechnology sector. Eight biotech companies priced IPOs from July through the end of September, raising $1.1 billion in total, according to data compiled by BioPharma Dive. That compares to four […]
September 7, 2023
Via: Biopharma DiveSeagen is the biotech sector’s leading developer of antibody-drug conjugates, which deliver cell-killing toxins to diseased cells by attaching them to an antibody that seeks out proteins on tumor cells. Its first, Adcetris, is on track to become a blockbuster […]
August 11, 2023
Via: Biopharma DiveThe success of cancer immunotherapies like Merck & Co.’s Keytruda and Bristol Myers’ Opdivo kicked off a broad search by biopharmaceutical companies for other ways to turn the immune system against cancer. One strategy that drew interest was targeting a […]